A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

To date, two chimeric antigen receptors (CAR)-T cell products from autologous T cells have been approved by The United States Food and Drug Administration (FDA). The case-by-case autologous T cell generation setting is largely considered as a pivotal restraining cause for its large-scale clinical us...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Stem Cell Res Ther
Main Authors: Razeghian, Ehsan, Nasution, Mahyuddin K. M., Rahman, Heshu Sulaiman, Gardanova, Zhanna R., Abdelbasset, Walid Kamal, Aravindhan, Surendar, Bokov, Dmitry O., Suksatan, Wanich, Nakhaei, Pooria, Shariatzadeh, Siavash, Marofi, Faroogh, Yazdanifar, Mahboubeh, Shamlou, Somayeh, Motavalli, Roza, Khiavi, Farhad Motavalli
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8317439/
https://ncbi.nlm.nih.gov/pubmed/34321099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13287-021-02510-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados